1414 - PD-L1 testing for access to Pembrolizumab for the treatment of locally advanced or metastatic NSCLC

Page last updated: 13 February 2017

Application Detail

Status

Open

Description of Medical Service

TImmunoHistoChemistry (IHC) test for evaluation of Programmed Cell Death 1 Ligand (PD-L1) expression to determine eligibility for treatment with Pembrolizumab.

Description of Medical Condition

Locally advanced or metastatic NSCLC (Stage IIIb/IV).

Reason for Application

New MBS item

Medical Service Type

Co-dependent technology

Previous Application Number

Not Applicable

Associated Documentation

Application Form

PICO Confirmation

Final Protocol (PDF 2875 KB)
Final Protocol (Word 922 KB)

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 824 KB)
Public Summary Document (Word 137 KB)

Meetings for this Application

PASC

13 August 2016

ESC

6 - 7 October 2016

MSAC

24 - 25 November 2016